-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $12.5 Price Target

Benzinga·03/19/2025 10:23:38
Listen to the news
HC Wainwright & Co. analyst Oren Livnat reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $12.5 price target.